BioCentury | Nov 14, 2019
Emerging Company Profile

Cedilla: degrading proteins by modulating protein stability

While most protein degradation companies are developing bifunctional molecules that directly induce ubiquitin-mediated degradation, Cedilla is taking a different approach with monovalent small molecules that trigger a broader range of degradation mechanisms. “The concept of...
BioCentury | Jun 20, 2019
Translation in Brief

Turning Tregs against cancer

Researchers from Massachusetts General Hospital found that inhibiting a signalosome complex in Treg cells could convert the immunosuppressive cell type into inflammatory cells in tumors, a strategy that could both increase the efficacy of checkpoint...
BioCentury | Jun 11, 2019
Distillery Therapeutics

Inhibiting BCL10 or MALT1 for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Mouse studies suggest inhibiting BCL10 or MALT1 could help treat melanoma. In a syngeneic mouse model of melanoma, Treg-specific knockout of BCL10 decreased tumor size compared with normal BCL10 expression....
BioCentury | May 8, 2019
Preclinical News

May 8 Preclinical Quick Takes: Moderna, WntRx, schizophrenia, heart attack

...PLC1 gamma - Phospholipase C1 gamma Mary Romeo, Staff Writer Fudan University Harvard University King's College London Moderna Inc. University of Cambridge B cell CLL lymphoma 9 (BCL9) Beta-catenin...
BioCentury | Feb 28, 2019
Distillery Therapeutics

Cancer

...testing inhibitors of BCL9, PYGO1 and PYGO2 in the models. TARGET/MARKER/PATHWAY: Adenomatous polyposis coli (APC); B cell CLL lymphoma 9 (BCL9)...
...email: o.sansom@beatson.gla.ac.uk Claire Quang Cancer Research UK Medical Research Council Laboratory of Molecular Biology (MRC LMB) Adenomatous polyposis coli (APC) B cell CLL lymphoma 9 (BCL9) Pygopus...
BioCentury | Jul 6, 2018
Preclinical News

New uses for marketed drugs in tough-to-treat indications

Two studies in Science Translational Medicine suggest three generics could be repurposed for difficult to treat indications. A paper from University of Edinburgh researchers showed that endothelial cell-targeted drugs simvastatin and perindopril could help treat...
BioCentury | Apr 10, 2018
Preclinical News

Researchers identify coding, non-coding driver mutations in MM

Scientists from the Institute of Cancer Research (London, U.K.) identified coding and non-coding driver mutations involved in newly diagnosed multiple myeloma, suggesting the genes could be targeted to treat the disease. The research was published...
BioCentury | Dec 1, 2017
Company News

Boehringer launches open-access preclinical platform

Boehringer Ingelheim GmbH (Ingelheim, Germany) launched a platform to provide researchers worldwide with open, free access to select molecules in the preclinical stage. The platform, opn.ME , comprises 19 compounds that Boehringer has deemed suitable for...
BioCentury | Nov 20, 2017
Company News

Boehringer launches open-access preclinical platform

Boehringer Ingelheim GmbH (Ingelheim, Germany) launched a platform to provide researchers worldwide with open and free access to select preclinical-stage molecules. The platform, opn.ME , comprises 19 compounds that Boehringer has deemed suitable for preclinical in...
BioCentury | May 16, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Tumor levels of eight proteins could help predict survival in melanoma. In patients, low tumor levels of eight tumor suppressors -- tumor necrosis factor α-induced protein 3 ( TNFAIP3 ; A20), PR domain...
Items per page:
1 - 10 of 29